- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05018728
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia (VoxSCAN)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sickle cell disease (SCD) is a genetic blood disorder that has profound effects on the brain. In the presence of chronic anemia, the brain microvasculature dilates in order to maintain adequate oxygen delivery to the tissue. As cerebral blood flow increases and the vasculature becomes maximally dilated, oxygen extraction fraction (OEF) increases to keep up with metabolic demand. Unfortunately, this state of maximized response leaves the brain vulnerable and ill-equipped to adapt to increased metabolic demand; consequently, the tissue is susceptible to infarction when blood flow/volume are insufficient to maintain sufficient oxygen metabolism.
Voxelotor is a first-in-class drug approved by the FDA for treatment of adults and children (aged four years and older) with SCD. This study will examine the effects of voxelotor on cerebral hemodynamics. The researchers hypothesize that as hemoglobin increases due to voxelotor, cerebral blood flow and oxygen extraction fraction will decrease. To test this hypothesis, measurements of brain blood flow, oxygen extraction, and oxygen metabolism will be made using a customized diffuse correlation spectroscopy and frequency domain near-infrared spectroscopy system (DCS/FDNIRS). This non-invasive, optical technique uses light to estimate an average oxygen saturation of the microvasculature, i.e., capillaries, arterioles, and venules.
All participants will receive voxelotor, administered orally once daily as tablets, dispersible tablets or as powder for oral suspension at a dose based on their body weight, for 12 weeks. Measurements of cerebral blood flow, oxygen extraction, and oxygen metabolism will be made at baseline (before starting drug), and at 4, and 12 weeks after the start of voxelotor.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Amy Tang, MD
- Phone Number: 404-785-1441
- Email: amy.tang@choa.org
Study Contact Backup
- Name: Erin Buckley, PhD
- Phone Number: (404) 727-4323
- Email: erin.buckley@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Children's Healthcare of Atlanta at Egleston
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Aflac Sickle Cell Comprehensive Clinics at Children's Healthcare of Atlanta, Scottish Rite
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed parental/guardian consent and participant assent/consent has been obtained per institutional review board (IRB)/Ethics Committee (EC) policy and requirements, consistent with International Conference on Harmonization (ICH) guidelines
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female participants, ages 4 to 30 years, inclusive
- Homozygous hemoglobin SS (HbSS) or hemoglobin S/beta^0 thalassemia (HbS/β^0 thal)
- Hemoglobin (Hb) ≤10.5 g/dL at baseline
- Concomitant hydroxyurea (HU) therapy is allowed if the dose has been stable for at least 3 months with no anticipated need for dose adjustments during the study and no sign of hematological toxicity
- Ability to take oral medication and willingness to adhere to daily voxelotor and scheduled DCS/NIRS assessments
- If sexually active and female, must agree to abstain from sexual intercourse or to use a highly effective method of contraception throughout the study period and for 30 days after discontinuation of study drug. If sexually active and male, must agree to abstain from sexual intercourse or willing to use barrier methods of contraception throughout the study period and for 30 days after discontinuation of study drug.
- Females of child-bearing potential, i.e., who have begun menstruation and are sexually active, are required to have a negative pregnancy test at screening before the initial administration of study drug.
Exclusion Criteria:
Any one of the following requiring medical attention within 14 days prior to signing the informed consent form (ICF):
- Vaso-occlusive crisis (VOC)
- Acute chest syndrome (ACS)
- Splenic sequestration crisis
- Dactylitis
- Requires chronic transfusion therapy
- Red blood cell (RBC) transfusion within 60 days of signing the ICF
- Renal dysfunction requiring chronic dialysis or creatinine ≥1.5 mg/dL
- Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4× upper limit of normal (ULN) for age
Clinically relevant cardiac abnormality, in the opinion of the Investigator, such as:
- Hemodynamically significant heart disease, e.g., congenital heart defect, uncompensated heart failure, or any unstable cardiac condition
- An arrhythmic heart condition requiring medical therapy
- Corrected QT interval by Fridericia (QTcF) >450 msec, congenital long QT syndrome, second- or third-degree heart block at rest (with the exception of asymptomatic Mobitz type I second degree heart block)
- Received an investigational drug within 30 days or 5 half-lives, whichever is longer, of signing the ICF
- Heavy smoker (defined as smoking more than 10 cigarettes/day or its nicotine equivalent including e-cigarettes)
- Unlikely to comply with the study procedures
- Other medical, psychological, or addictive condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or pharmacokinetics (PK) of the investigational drug, prevent compliance with the study protocol, or preclude informed consent
- Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
- History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
Clinically significant bacterial, fungal, parasitic, or viral infection currently receiving or that will require therapy
- Participants with acute bacterial infection requiring antibiotic use should delay screening until the course of antibiotic therapy has been completed and the infection has resolved, in the opinion of the investigator
- Known active hepatitis A, B, or C infection or human immunodeficiency virus (HIV)-positive; known active
- Known active malaria
- Pregnant patients
- Evidence of abnormal high blood flow velocities on transcranial doppler (TCD) of 200 cm/sec or more
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Voxelotor
Children with sickle cell anemia taking voxelotor for 12 weeks.
|
Voxelotor is taken orally once a day.
Participants 12 years or older will take 1500 mg/day.
Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cerebral blood flow (CBF)
Time Frame: Baseline, Weeks 4 and 12
|
CBF will be measured by diffuse correlation spectroscopy and frequency domain near-infrared spectroscopy (DCS/FDNIRS).
|
Baseline, Weeks 4 and 12
|
Change in oxygen extraction fraction (OEF)
Time Frame: Baseline, Weeks 4 and 12
|
OEF will be measured by DCS/FDNIRS.
OEF is defined as the difference between arterial and venous oxygen content and it increases to keep up with metabolic demand.
|
Baseline, Weeks 4 and 12
|
Change in cerebral metabolic rate of oxygen (CMRO2)
Time Frame: Baseline, Weeks 4 and 12
|
CMRO2 will be measured by DCS/FDNIRS.
CMRO2 is the rate that the brain consumes oxygen and is a marker of brain health.
|
Baseline, Weeks 4 and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total hemoglobin
Time Frame: Baseline, Weeks 4 and 12
|
Total hemoglobin levels will be assessed and the correlation between changes in CBF, OEF and CMRO2 and change in hemoglobin at 4, 8 and 12 weeks will be evaluated.
|
Baseline, Weeks 4 and 12
|
Change in RBC content of voxelotor-modified hemoglobin
Time Frame: Baseline, Weeks 4 and 12
|
RBC levels in voxelotor-modified hemoglobin will be assessed and the correlation between changes in CBF, OEF and CMRO2 and change in voxelotor-modified hemoglobin at 4, 8 and 12 weeks will be evaluated.
|
Baseline, Weeks 4 and 12
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002483
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Anemia in Children
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSickle Cell Anemia in ChildrenUganda
-
Al-Neelain UniversityUniversity of KhartoumUnknownSickle Cell Anemia in ChildrenSudan
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
University of Mississippi Medical CenterUniversity of Alabama at BirminghamRecruiting
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
Children's Hospital Medical Center, CincinnatiBugando Medical Centre; The American Society of HematologyEnrolling by invitationSickle Cell Anemia in ChildrenUnited States, Tanzania
-
Children's Hospital of PhiladelphiaPenn State University; Newcastle UniversityCompletedSickle Cell Anemia in Children | Vitamin A Deficiency in ChildrenUnited States
-
Liverpool School of Tropical MedicineUniversity of Bergen; Indiana University; Makerere University; University of Malawi and other collaboratorsCompletedMalaria | Sickle Cell Anemia in ChildrenUganda, Malawi
-
Vanderbilt University Medical CenterAminu Kano Teaching Hospital; Bayero University Kano, Nigeria; Murtala Muhammed...CompletedStroke | Neurologic Manifestations | Sickle Cell Disease | Sickle Cell Anemia | Neurological Morbidity | Sickle Cell Anemia in ChildrenNigeria, United States
Clinical Trials on Voxelotor
-
PfizerPfizerRecruitingSickle Cell DiseaseUnited States
-
University of Illinois at ChicagoGlobal Blood TherapeuticsRecruitingSickle Cell Disease | Sickle Cell NephropathyUnited States
-
PfizerPfizerSuspendedSickle Cell DiseaseUnited States, Lebanon, United Kingdom
-
PfizerActive, not recruitingSickle Cell DiseaseUnited States, Oman, United Kingdom, France, Egypt, Ghana, Italy, Kenya, Nigeria, Saudi Arabia
-
PfizerNo longer availableSickle Cell DiseaseUnited States
-
PfizerPfizerCompletedSickle Cell DiseaseUnited States
-
PfizerPfizerRecruitingSickle Cell DiseaseLebanon, United Kingdom, United States, Nigeria, Egypt
-
Elizabeth Yang, MD, PhDUniversity of California, San Francisco; Global Blood Therapeutics; PediatrixCompleted
-
PfizerTerminatedSickle Cell DiseaseUnited Kingdom
-
Duke UniversityTerminatedAcute Lung Injury | End Stage Lung DiseaseUnited States